The impact of psoriasis on wellbeing and clinical outcomes in juvenile psoriatic arthritis

• Published in: Rheumatology (Oxford, England) England), 2024-05, Vol.63 (5), p.1273-1280
• Main Authors: Low, Jie Man, Hyrich, Kimme L, Ciurtin, Coziana, McErlane, Flora, Wedderburn, Lucy R, Geifman, Nophar, Shoop-Worrall, Stephanie J W
• Format: Article
• Language: English
• Subjects: Adolescent; Arthritis, Juvenile - complications; Arthritis, Juvenile - psychology; Arthritis, Psoriatic - complications; Arthritis, Psoriatic - psychology; Child; Clinical Science; Depression - etiology; Female; Humans; Male; Patient Reported Outcome Measures; Prospective Studies; Psoriasis - complications; Psoriasis - psychology; Quality of Life; Severity of Illness Index
• ISSN: 1462-0324; 1462-0332; 1462-0332
• DOI: 10.1093/rheumatology/kead370

Juvenile PsA (JPsA) has varied clinical features that are distinctive from other JIA categories. This study investigates whether such features impact patient-reported and clinical outcomes. Children and young people (CYP) were selected if recruited to the Childhood Arthritis Prospective Study, a UK multicentre JIA inception cohort, between January 2001 and March 2018. At diagnosis, patient/parent-reported outcomes (as age-appropriate) included the parental global assessment (10 cm visual analogue scale), functional ability (Childhood Health Assessment Questionnaire (CHAQ)), pain (10 cm visual analogue scale), health-related quality of life (Child Health Questionnaire PF50 psychosocial score), mood/depressive symptoms (Moods and Feelings Questionnaire) and parent psychosocial health (General Health Questionnaire 30). Three-year outcome trajectories have previously been defined using active joint counts, physician and parent global assessments (PGA and PaGA, respectively). Patient-reported outcomes and outcome trajectories were compared in (i) CYP with JPsA vs other JIA categories and (ii) CYP within JPsA, with and without psoriasis via multivariable linear regression. There were no significant differences in patient-reported outcomes at diagnosis between CYP with JPsA and non-JPsA. Within JPsA, those with psoriasis had more depressive symptoms (coefficient = 9.8; 95% CI: 0.5, 19.0) than those without psoriasis at diagnosis. CYP with JPsA had 2.3 times the odds of persistent high PaGA than other ILAR categories, despite improving joint counts and PGA (95% CI: 1.2, 4.6). CYP with psoriasis at JPsA diagnosis report worse mood, supporting a greater disease impact in those with both skin and joint involvement. Multidisciplinary care with added focus to support wellbeing in children with JPsA plus psoriasis may help improve these outcomes.